JPRN-jRCT2080221686未知3 期
Clinical phase III study of YP-18 for febrile neutropenia
试验速览
- 阶段
- 3 期
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •[Start of pre-observation period] Patients satisfying all the following criteria:
- •(1) Patients diagnosed as histologically or cytologically malignant solid tumor or hematopoietic organ tumor
- •(2) Patients expected to undergo or undergoing the treatment with anticancer drug or hematopoietic stem cell transplantation (only for patients undergoing autologous transplantation), who are expected to induce febrile neutropenia during the treatment
- •(3) Patients aged 9 months or older (at acquisition of consent)
- •(4) Patients expected to survive during participation in the study
- •[At start of administration of the study drug] Subjects satisfying all the following criteria:
- •(1) Subjects satisfying the following criteria:
- •1) The body temperature (axillary temperature) determined before administration of the study drug is 38 or higher, or the fever of 37.5 or higher of unknown cause continues for more than 1 hour
- •2) The neutrophil count before start of administration of the study drug is less than 500/mm3, or less than 1000/mm3 which is expected to reduce to less than 500/mm3
- •(2) Subjects satisfying the following criteria based on the data within 7 days before start of administration of the study drug:
- •1) In the hepatic functions, either of AST(GOT) or ALT(GPT) does not exceed 5 times as large as the upper limit of institutional standard value, or the total bilirubin does not exceed 1.5 times as large as the upper limit of institutional standard value.
- •2) In the renal functions, the serum creatinine value does not exceed 1.5 times as large as the upper limit of institutional standard value, and in adults, the estimated value for creatinine clearance is not less than 40 mL/min.
- •In the absence of standard value for serum creatinine in children by age in the institution concerned, moreover, it does not exceed 1.5 times as large as the upper limit of standard value with reference to the standard value for serum creatinine in children by age established by the Japanese Society for Pediatric Nephrology.
- •(3) Hospitalized patients (however, can be discharged from hospital after the post-observation period)
排除标准
- •[At start of pre-observation period] Patients falling into any of the following criteria:
- •(1) Patients with a history of allergy or serious adverse reaction to the ingredients of study drug and beta-lactam antimicrobial drug
- •(2) Patients with infectious mononucleosis
- •(3) Patients who have undergone the treatment of study drug after giving the consent for this clinical study (reenrollment is permissible unless YP-18 has been administered despite of giving the consent for this clinical study)
- •(4) Patients who participated in the other clinical studies within the past 28 days
- •(5) Patients considered by the investigator or subinvestigator to be unsuitable as the subject of the clinical study
- •[At start of administration of the study drug] Subjects falling into any of the following criteria:
- •(1) Subjects considered that the pretreatment with other antimicrobial drug, antifungal drug, antiviral drug, etc. is effective for the episode of existing febrile neutropenia and the symptoms are already improving. Not applicable if the pretreatment is considered ineffective, however. Moreover, the subjects receiving Zosyn for Intravenous Injection (tazobactam sodium/piperacillin sodium) should be excluded irrespective of the presence or absence of efficacy.
- •(2) Patients with infections with the pathogens insusceptible to this drug or resistant strains, including MRSA, fungi, viruses, etc. and considered to have difficulty in expecting the efficacy of this drug
- •(3) Pregnant women, lactating women, or women with the possibility of pregnancy
- •(4) Subjects considered by the investigator or subinvestigator to be unsuitable for the clinical study
研究者
相似试验
未知
3 期
Phase III Clinical Study of YP-18 in Intra-Abdominal InfectionsJPRN-jRCT2080221068Taiho Pharmaceutical Co., Ltd.100
进行中（未招募）
1 期
Domestic Phase I/IIa Investigator-initiated Clinical Trials to Evaluate the Safety of 18F-PSMA-1007 in Healthy Adults and Subjects with Prostate CancerJPRN-jRCT2032210711Tateishi Ukihide13
已完成
2 期
Study of Clinical Usefulness of 18F-fluorothymidine(FLT) PET/CT in Ditection of Peritoneal Metastases of Gastric CancerJPRN-UMIN000009329Department of Gastrointestinal Oncology, National Cancer Center Hospital in Japan40
招募中
不适用
Clinical study to evaluate the usefulness of 18F-FBPA-PET for patient selection and expanding indication for BNCTHead and Neck Cancer,Malignant gliomaJPRN-UMIN000035976Southern TOHOKU BNCT Research Center20
尚未招募
1 期
Cancelled by the investigator Study for the Effectiveness and Safety of Compound Yuxingcao Mixture in the Treatment of the Novel Coronavirus Pneumonia (COVID-19)ITMCTR2000003079Affiliated Hospital of traditional Chinese and Western Medicine Nanjing University of Chinese Medicine